Retatrutide in Abu Dhabi: Formats, COA & AED Pricing
The Abu Dhabi-specific view for research buyers: research-use status, six formats, batch COA proof, AED price tiers, and prepaid tracked next-day cold-chain delivery to the capital.
As of July 7, 2026, "retatrutide Abu Dhabi" is a research-use sourcing and delivery question, not a pharmacy-access question. The capital has no approved retatrutide medicine route. What Abu Dhabi research buyers need is the same proof stack used across the Emirates: a published Janoshik COA, transparent AED pricing, and a reliable prepaid cold-chain courier that keeps material at temperature on the Dubai-to-Abu Dhabi leg. For the consolidated commercial overview, use the Retatrutide UAE hub.
Prefer the full UAE catalog and live stock first? See the Retatrutide UAE category page, the Retatrutide in Dubai guide, the flagship Retatrutide 30mg Pen, and the COA library.
Is Retatrutide Available in Abu Dhabi for Research Use?
Quick answer: Retatrutide is not MoHAP-approved and is not sold through Abu Dhabi pharmacies or clinics. Research-grade material is supplied by Remy Peptides for in-vitro laboratory research only, dispatched from Dubai and delivered next-day to Abu Dhabi by prepaid tracked cold-chain courier under UAE MoHAP Circular 17/2022.
Retatrutide (LY-3437943) is an investigational triple-agonist peptide, not a licensed medicine in the UAE, so it does not appear on Abu Dhabi pharmacy shelves. Research institutions, university labs, and private research facilities in Abu Dhabi that require the compound for in-vitro work source it through research-use suppliers under the in-vitro framing of MoHAP Circular 17/2022. Remy Peptides operates from Dubai (Al Barsha 1), supplies retatrutide strictly for laboratory research, and ships to Abu Dhabi and the wider UAE with tracked cold-chain logistics. Batch purity is verifiable through published Janoshik Analytical COAs before any order is placed.
- Retatrutide is investigational and not stocked in Abu Dhabi pharmacies as of July 7, 2026 — access is research-use only.
- The in-stock research lane is the Retatrutide 30mg prefilled pen (300 clicks at 0.1mg/click), batch RETP002 at 99.262% HPLC; other pens and vials are reference-only when out of stock.
- Abu Dhabi orders arrive next-day by prepaid tracked cold-chain courier — cash on delivery is a Dubai-only option and is not offered for Abu Dhabi.
- Pricing is transparent in AED: AED 1,600 single 30mg pen, down to AED 1,300/pen at the 5+ tier, with the wider catalog spanning AED 350–2,000.
- Every released batch is backed by an independent Janoshik HPLC certificate of analysis published before purchase.
Retatrutide Research-Use Status in the UAE and Abu Dhabi
Quick answer: Retatrutide (LY-3437943) is Eli Lilly's investigational once-weekly triple agonist targeting GLP-1, GIP, and glucagon receptors. It remains in Phase 3 development (TRIUMPH programme) and is not approved by the FDA, EMA, or UAE MoHAP. Remy Peptides supplies research-grade formats for in-vitro laboratory use only.
Retatrutide simultaneously activates three metabolic receptors — GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). In a pivotal Phase 2 trial published in the New England Journal of Medicine (DOI: 10.1056/NEJMoa2301972), the highest dose reported a mean 24.2% body-weight reduction over 48 weeks. Eli Lilly's Phase 3 TRIUMPH programme has continued to read out through 2026, but Lilly has not announced an NDA filing date, and retatrutide remains investigational without FDA, EMA, or UAE approval.
For Abu Dhabi, the practical consequence is unchanged: there is no approved retatrutide medicine and no clinical dispensing route in the capital. Any UAE clinical availability would require separate regulatory review by the UAE Ministry of Health and Prevention (MoHAP) after Phase 3 completion. Until then, retatrutide in Abu Dhabi is a research-use compound only. The full regulatory timeline is tracked on our retatrutide approval status page, and UAE study listings are covered in the retatrutide clinical trials UAE review.
How Abu Dhabi Research Buyers Source Retatrutide
Quick answer: Abu Dhabi researchers source retatrutide from Remy Peptides for in-vitro laboratory use only. As a pre-approval investigational compound it is not sold through pharmacies or clinics; batch purity is verifiable through published Janoshik COAs, and orders ship next-day to Abu Dhabi from the Dubai facility.
Prefilled pens are the preferred format for Abu Dhabi labs for the same reasons they are in Dubai: they remove the reconstitution step that introduces the primary contamination vector, provide click-based precision (0.1mg per click on the 30mg pen), and travel in temperature-controlled packaging that protects material integrity across the UAE summer. Before paying any supplier, Abu Dhabi buyers should check a batch-specific Janoshik COA with a re-verifiable HPLC purity value, visible AED pricing and format specs, a stated 2–8°C cold-chain standard, and a named UAE base with verified contact channels. Our supplier comparison and step-by-step buying checklist apply identically to Abu Dhabi procurement.
Retatrutide Pricing in AED for Abu Dhabi
Quick answer: Live research-use retatrutide spans AED 350 to AED 2,000 across six formats; the in-stock flagship 30mg pen is AED 1,600 for a single pen, dropping to AED 1,300/pen at the 5+ tier. Every released batch publishes Janoshik HPLC proof, and UAE delivery to Abu Dhabi is free on AED 1,000+ orders.
Pricing for Abu Dhabi is the same transparent AED tier structure used across the Emirates — the capital does not carry a delivery surcharge on qualifying orders. All prices are in AED (United Arab Emirates Dirham) and include free UAE cold-chain delivery on AED 1,000+ orders.
- 1 pen: AED 1,600 (30mg) / AED 1,200 (20mg)
- 2-pack: AED 1,450/pen (30mg) / AED 1,100/pen (20mg) — save AED 300 (30mg) / AED 200 (20mg)
- 5+ pack: AED 1,300/pen (30mg) / AED 1,000/pen (20mg) — save AED 1,500 (30mg) / AED 1,000 (20mg)
Across the wider catalog, the 10mg vial references AED 350 (out of stock) and the 40mg vial references AED 900–1,000/vial depending on quantity (out of stock), placing the full research-use range at AED 350 to AED 2,000. As of July 7, 2026 the 30mg pen is the active in-stock research product; the 20mg, 10mg, and 40mg pens and both vials are reference-only — use Notify me on each product page for restock alerts. Live batch-linked tiers are on the Retatrutide UAE pricing matrix.
Delivery to Abu Dhabi: Prepaid Tracked Cold-Chain
Quick answer: Abu Dhabi orders are dispatched from Dubai and arrive next-day by prepaid tracked cold-chain courier in insulated, temperature-controlled packaging, with a tracking number on every shipment. Payment is prepaid by secure card link or USDT (TRC-20). Cash on delivery is a Dubai-only option and is not offered for Abu Dhabi.
Remy Peptides dispatches all research peptide orders from its Dubai facility (Al Barsha 1) using insulated, temperature-controlled packaging. For Abu Dhabi, the standard service is next-day delivery with a tracking number, covering the capital and surrounding areas including Al Reem Island, Yas Island, Khalifa City, Mussafah, and the Corniche district. Every shipment maintains cold-chain integrity from dispatch to laboratory receipt — critical during UAE summer months when ambient temperatures regularly exceed 45°C.
Abu Dhabi orders are prepaid: settle by secure card payment link or USDT (TRC-20) before dispatch. Cash-on-delivery is limited to Dubai and is not available for the capital. WhatsApp support handles order tracking and delivery coordination 7 days a week, 10 AM to 10 PM UAE time. Emirate-by-emirate windows are summarised on the Abu Dhabi delivery reference.
COA and Purity Proof for Abu Dhabi Labs
Every released Remy Peptides retatrutide format is HPLC-verified by Janoshik Analytical, an independent third-party laboratory based in the Czech Republic, with a batch-specific Certificate of Analysis published before purchase and shipped with each order. The flagship 30mg pen batch RETP002 tests at 99.262% HPLC; published sibling batches include the 20mg pen RET-20-C-2604-001 at 99.841% and the 40mg vial RT-40-V-001 at 99.692% (sterility-tested). Abu Dhabi buyers can re-verify any published batch themselves on janoshik.com and cross-check official channels via contact verification.
Retatrutide vs Semaglutide and Tirzepatide in Trial Data
Abu Dhabi researchers comparing metabolic receptor agonists usually start from the receptor count, which correlates with observed efficacy in published trials. The table below summarises reported trial figures for context; these are clinical-trial observations, not product claims or guidance for use.
| Feature | Semaglutide (Wegovy) | Tirzepatide (Mounjaro/Zepbound) | Retatrutide |
|---|---|---|---|
| Receptors targeted | GLP-1 only (single agonist) | GLP-1 + GIP (dual agonist) | GLP-1 + GIP + glucagon (triple agonist) |
| Reported mean weight reduction in trials | ~15% at 68 weeks (STEP 1, phase 3) | ~21% at 72 weeks (SURMOUNT-1, 15 mg, phase 3) | ~24% at 48 weeks (phase 2, NEJM 2023) |
| Approval status | FDA/EMA approved for weight management | FDA/EMA approved for weight management | Investigational — not approved by FDA, EMA, or UAE MoHAP |
| Mechanism note | Appetite/satiety via GLP-1 pathway | Adds GIP-driven insulin and appetite effects | Adds glucagon agonism, linked in trials to higher energy expenditure and hepatic lipid oxidation |
For the full receptor, dosing, and trial breakdown, see our Retatrutide vs Tirzepatide vs CagriSema comparison. For a broader regional read, this page sits alongside the Retatrutide in Dubai guide and the Buy Retatrutide Saudi Arabia verification page.
Our Research Standards
This article combines peer-reviewed retatrutide trial literature with a July 7, 2026 review of UAE research-use sourcing, AED pricing, and Abu Dhabi delivery logistics. Product proof is anchored to the Retatrutide 30mg Pen from Remy Peptides and Janoshik COA RETP002 (99.262% HPLC). Retatrutide remains investigational; nothing here is a treatment, dosing, or human-use claim. Read our editorial policy →
References
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972.
- ClinicalTrials.gov. TRIUMPH retatrutide clinical trial program. NCT05929066.
- Remy Peptides. Retatrutide 30mg Pen and Janoshik COA batch RETP002 (99.262% HPLC). Reviewed July 7, 2026.
- Remy Peptides. Retatrutide UAE formats, AED pricing, and live stock status. Reviewed July 7, 2026.
For the research-only side of this market, use the Retatrutide UAE hub, the Retatrutide 30mg Pen, the COA library, and contact verification together.